Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30200298 | 0.98 | MAOA (0.39) | MAOAMAOBFTOHTTCA1 | |
| Hydrochloric Acid SCHEMBL28731292 | 0.98 | MAOA (0.39) | MAOAMAOBFTOHTTCA1 | |
| SCHEMBL448219 | 0.79 | MAOA (0.41) | MAOAMAOBFTOKCNA3FADS1 | |
| SCHEMBL97155 | 0.79 | MAOA (0.45) | MAOAMAOBFTOCYP2A6KCNA3 | |
| SCHEMBL28731290 | 0.78 | ALDH1A1 (0.37) | HTTKDM4EALDH1A1GAAMAPT | |
| SCHEMBL31231044 | 0.75 | CYP2A6 (0.42) | MAOAMAOBFTOCYP2A6KCNA3 | |
| SCHEMBL20680998 | 0.72 | HTT (0.42) | HTTALDH1A1 | |
| SCHEMBL1998501 | 0.72 | MAOB (0.40) | MAOAMAOBFTOCA1CA2 | |
| SCHEMBL29489124 | 0.71 | CA1 (0.54) | HTTCA1CA2TSHRKDM4E | |
| SCHEMBL45954 | 0.71 | CA1 (0.54) | HTTCA1CA2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | TSINGHUA UNIVERSITY (CN) | 2025-09-18 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-4509494-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | Tsinghua University (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-0923568-B9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | ALTANA PHARMA AG (DE) | 2003-08-13 | — | — | EP | disclosed |
| EP-0923568-B1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | ALTANA PHARMA AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002026747-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINE DERIVATIVES WITH 5-HT RECEPTOR AFFINITY | KNOLL GMBH (DE) | 2002-04-04 | — | — | WO | disclosed |
| US-6211203-B1 | RESPIRATORY SYSTEM DISORDERS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-04-03 | — | — | US | disclosed |
| EP-0923568-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998007715-A9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998007715-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | ROCK1, ROCK2, RHOA | MAOA 852/4885MAOB 775/4885FTO 4408/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | MAOA 1952/4885MAOB 1780/4885FTO 1812/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | MAOA 1125/4885MAOB 640/4885FTO 594/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | MAOA 3656/4885MAOB 3480/4885FTO 3885/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | MAOA 3975/4885MAOB 4006/4885FTO 3894/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | MAOA 3656/4885MAOB 3480/4885FTO 3885/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | MAOA 142/4885MAOB 693/4885FTO 4581/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | MAOA 3732/4885MAOB 3533/4885FTO 4326/4885 |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | ACE, PLP2, ACE2 | MAOA 1084/4885MAOB 1967/4885FTO 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.